Phase I trial finds topical PXS-6302 generally well tolerated in established skin scars
University of Western Australia's Burn Injury Research Unit with the Fiona Wood Foundation reports that topical pan-lysyl oxidase inhibition with PXS-6302 was generally well tolerated over three months and altered extracellular ...
